
JOHN WILEY & SONS, LTD., THE ATRIUM, SOUTHERN GATE, CHICHESTER P019 8SQ, UK

*****PROOF OF YOUR ARTICLE ATTACHED, PLEASE READ CAREFULLY*****

After receipt of your corrections your article will be published initially within the online version of the journal.

**PLEASE AIM TO RETURN YOUR CORRECTIONS WITHIN 48 HOURS OF RECEIPT OF YOUR PROOF, THIS WILL ENSURE THAT THERE ARE NO UNNECESSARY DELAYS IN THE PUBLICATION OF YOUR ARTICLE**

- ❑ **READ PROOFS CAREFULLY**

**ONCE PUBLISHED ONLINE OR IN PRINT IT IS NOT POSSIBLE TO MAKE ANY FURTHER CORRECTIONS TO YOUR ARTICLE**

  - This will be your only chance to correct your proof
  - Please note that the volume and page numbers shown on the proofs are for position only

- ❑ **ANSWER ALL QUERIES ON PROOFS** (Queries are attached as the last page of your proof.)

  - List all corrections and send back via e-mail to the production contact as detailed in the covering e-mail, or mark all corrections directly on the proofs and send the scanned copy via e-mail. Please do not send corrections by fax or post

- ❑ **CHECK FIGURES AND TABLES CAREFULLY**

  - Check size, numbering, and orientation of figures
  - All images in the PDF are downsampled (reduced to lower resolution and file size) to facilitate Internet delivery. These images will appear at higher resolution and sharpness in the printed article
  - Review figure legends to ensure that they are complete
  - Check all tables. Review layout, title, and footnotes

- ❑ **COMPLETE COPYRIGHT TRANSFER AGREEMENT (CTA) if you have not already signed one**

  - Please send a scanned signed copy with your proofs by e-mail. **Your article cannot be published unless we have received the signed CTA**

- ❑ **OFFPRINTS**

  - Free access to the final PDF offprint or your article will be available via Author Services only. Please therefore sign up for Author Services if you would like to access your article PDF offprint and enjoy the many other benefits the service offers.

**Additional reprint and journal issue purchases**

- Should you wish to purchase additional copies of your article, please click on the link and follow the instructions provided: http://offprint.cosprinters.com/cos/bw/
- Corresponding authors are invited to inform their co-authors of the reprint options available.
- Please note that regardless of the form in which they are acquired, reprints should not be resold, nor further disseminated in electronic form, nor deployed in part or in whole in any marketing, promotional or educational contexts without authorization from Wiley. Permissions requests should be directed to mailto: permissionsuk@wiley.com
- For information about 'Pay-Per-View and Article Select' click on the following link: http://olabout.wiley.com/WileyCDA/Section/id-404512.html

**Journal of Pathology**
*J Pathol* 2016; **0:** 000–000
Published online in Wiley Online Library
(wileyonlinelibrary.com) DOI: 10.1002/path.4746

**INVITED COMMENTARY**

# Cutaneous cylindroma: it's all about MYB#

AQ1 Gabriele Corda [1,2] and Arturo Sala [1,2,*]

[1] College of Health and Life Sciences, Brunel University, London, UK
[2] Institute of Environment, Health and Societies, Brunel University, London, UK

*Correspondence to: A Sala, Institute of Environment, Health and Societies, College of Health and Life Sciences, Heinz Wolff Building, Brunel University, London UB8 3PH, UK. E-mail: arturo.sala@brunel.ac.uk

#Invited commentary for Rajan N, Andersson MK, Sinclair N, *et al.* Overexpression of *MYB* drives proliferation of *CYLD*-defective cylindroma cells. *J Pathol* 2016; **239:** 197–205. AQ2

## Abstract

**Cutaneous cylindroma is a rare benign tumour that occasionally turns into malignant cylindrocarcinoma. The cancer can be sporadic or emerge in the context of Brooke–Spiegler syndrome (BSS), an inheritable condition characterized by mutation of the gene *CYLD*, encoding a tumour suppressor protein that controls the activity of the transcription factor NF-kB. Sporadic cylindromas present histological features shared with adenoid cystic carcinoma (ACC), a head and neck cancer originating from salivary or other exocrine glands. Like ACCs, sporadic cylindromas express, although at lower frequency, the aberrant fusion transcript MYB–NFIB. In a paper recently published in the *Journal of Pathology*, the research teams led by Neil Rajan and Goran Stenman demonstrate that CYLD-defective cyclindromas in BSS patients are negative for the MYB–NFIB fusion. Only the wild-type MYB oncoprotein is activated in the majority of these tumours. RNA interference studies in cells derived from BSS patients indicate that ablating MYB expression results in a striking reduction of cylindroma cell proliferation, suggesting that MYB plays a pivotal role in the biology of this cancer. The take-home message of the study is that activation of MYB, in its wild-type form or fusion derivatives, is a common feature of spontaneous and hereditary cylindromas, constituting a potentially actionable therapeutic target.**


**Keywords:** MYB; cylindroma; Brooke–Spiegler syndrome; CYLD; adenoid cystic carcinoma

Received 25 April 2016; Accepted 11 May 2016

*No conflicts of interest were declared.*



Familial cylindromatosis, also defined as Brooke–Spiegler syndrome (BSS), is associated with mutation of the tumour suppressor gene *CYLD* [1]. Malignant transformation of cylindromas is rare, but often results in the development of high-grade metastatic tumours that drastically reduce patient survival. The treatment for these neoplasms is limited to broad margin excision or high-dose radiotherapy for unresectable tumours. A deeper understanding of the pathophysiology of cylindromas is essential if new useful therapeutic targets are to be identified.

It has been suggested that the loss of heterozygosity in the *CYLD* locus accounts for the majority of both familiar and sporadic cylindromas, but the molecular pathways deregulated in these tumours are still poorly characterized [1,2]. Histological and morphological similarities with adenoid cystic carcinomas (ACCs) led to the hypothesis that the two cancer types might harbour common molecular alterations. Indeed, a fraction of sporadic cylindromas and approximately half of ACCs express the *MYB–NFIB* fusion gene [3]. c-MYB (hereafter indicated by MYB) is a transcription factor encoded by a gene belonging to a small family that also includes *MYBL2* (encoding B-MYB) and *MYBL1* (encoding A-MYB). They share a DNA binding domain that recognizes the consensus sequence C/TAACNG, frequently observed in the enhancers of genes associated with cell cycle progression, regulation of cell survival and lineage specification [4]. It is likely that spatio-temporal distribution, more than structural differences, explains the requirement of the different MYBs in organism and tissue development. There is a growing body of evidence suggesting that MYB proteins play an important role in human cancer, with different family members mutated or activated in leukaemia, neuroblastoma, brain, colon, liver and breast cancers [5–8]. The majority of ACCs display rearrangements of the *MYB* locus, with recurrent fusions of MYB with the transcription factor NFIB [9]. More recently, it has been shown that *MYB–NFIB* fusion-negative, but *MYB* locus rearranged, ACCs display activation of *MYB* caused by the translocation of super-enhancers near the gene [10]. Thus, activation of *MYB* might explain the similar histological and morphological features of ACCs and cylindromas.




Color

**Figure 1.** Different modalities of MYB activation in familial and sporadic cylindromas: (left panel) in normal epidermal cells the tumour suppressor gene *CYLD* inhibits NF-kB, HDACs and possibly additional molecules and pathways (indicated by the question marks); (centre panel) mutations of *CYLD* in familial cylindromas disrupt the block on NF-kB, HDACs and/or other molecular pathways, leading to the activation of *MYB* (green arrows) and the anti-apoptotic proteins Bcl2 and Birc3; (right panel) in sporadic cylindromas and ACCs the t(6:9) or other translocations involving the *MYB* locus activate expression of the MYB oncoprotein via the formation of fusion genes or epigenetic rearrangements

In a study recently published in the *Journal of Pathology*, Rajan *et al* [11] investigated the role of *MYB* in CYLD-defective cylindromas and spyroadenomas. The same group previously observed a relatively high incidence of *MYB–NFIB* fusion transcripts in sporadic cylindromas [3]. Surprisingly, when the researchers analysed a cohort of samples deriving from CYLD-defective familial tumours, they did not detect *MYB–NFIB* fusion transcripts or rearrangements of the *MYB* locus. However, immunohistochemical analysis revealed strong nuclear expression of MYB in the majority of BSS tumours. Importantly, they verified that the expression of the oncoprotein is significantly higher in cancer than in normal skin. To verify the functional significance of MYB activation in cylindromas, the research team implemented RNA interference experiments in which they depleted the expression of *MYB* in primary tumour cultures derived from patients. Reduced *MYB* expression caused a significant decrease in tumour cell proliferation. These findings confirm that overexpression of MYB is a key feature of familial cylindromas and link the mutation of the tumour suppressor gene *CYLD* with MYB activation. Heterozygosity of the *CYLD* locus has been observed in a fraction of sporadic cases of cylindroma [12]. Since *MYB–NFIB* fusions are also observed in these tumours, it would be interesting to assess whether these chromosomal rearrangements are mutually exclusive with *CYLD* alterations. This would corroborate the hypothesis that increased expression of MYB, either as MYB–NFIB fusion or wild-type protein, is the causative event in these tumours.

CYLD is a de-ubiquitylating enzyme that regulates protein stability by removing poly-ubiquitin chains from substrates. CYLD loss has been shown to promote survival or proliferation of different cell types, supporting the hypothesis that it may act as a tumour suppressor. Prior to the study by Rajan *et al* [11], there was no evidence of a link between MYB and CYLD pathways in cancer cells. The authors of the study suggest that a possible explanation for the activation of *MYB* in *CYLD* mutant cells may rest in the loss of control of NF-kB activity. Indeed, *CYLD* inactivation causes increased NF-kB signalling and it was previously reported that the *MYB* promoter contains NF-kB binding sites, transactivated by NF-kB [13,14]. Perplexingly, however, Rajan *et al* [11] did not observe perturbation of *MYB* expression after drugging NF-kB in cylindroma cells, suggesting that another circuitry linking *CYLD* and *MYB* must be operating in cutaneous tumours. It is tempting to speculate that *CYLD* could alter chromatin dynamics in the *MYB* locus, since recent studies have revealed that *CYLD* negatively controls the activity of histone deacetylases HDAC6 and HDAC7 in mammalian cells [15,16]. Intriguingly, the pan-HDAC inhibitor Givinostat has been shown to strongly down-regulate MYB expression in leukaemic cells, indicating that histone acetylation changes might be crucially linked to *MYB* activation in cancer. This hypothesis is corroborated by a study demonstrating epigenetic activation of the *MYB* locus in MYB–NFIB-negative, but translocation-positive, ACCs [10]. Taken together, these studies strongly indicate that the pathogenic cause of cylindromas and ACCs is the activation of *MYB*.

Of course, there are still important questions awaiting an answer: is MYB necessary and sufficient for the transformation of cutaneous and glandular cells? What are the critical MYB target genes? To start answering the latter question, Rajan *et al* [11] conducted gene expression analyses on previously published microarray datasets. Among others, they detected two MYB target genes

involved in the control of apoptosis, *BCL2* and *BIRC3*, which were significantly up-regulated in cylindromas compared to normal skin. Satisfyingly, ablation of MYB reduced the expression of *BCL2* and *BIRC3* in cylindroma cells, suggesting that MYB also precipitates cutaneous tumourigenesis through inhibition of apoptosis. Whether or not MYB is the key driver of cyclindroma, or other head and neck cancers, will only be established by developing appropriate transgenic models or by implementing DNA-editing strategies that reproduce the genomic rearrangements leading to *MYB* activation.

These findings of Rajan *et al* [11] give hope to patients affected by malignant cylindroma. Small-molecule inhibitors of MYB are being developed, some of which show promise in preclinical experiments. For example, the multi-kinase inhibitor Rigosertib induces selective killing of diffuse large B cell lymphoma by suppressing TRAF6 and MYB [17]. Interestingly, TRAF6 is an adaptor protein involved in tumour development and was previously shown to be a *CYLD* target protein [18]. It will be important to assess whether Rigosertib kills or reduces the proliferation of cylindroma cells in preclinical experiments.

## Author contributions

Both authors were involved in preparing the manuscript.

## References


1. Bignell GR, Warren W, Seal S, *et al.* Identification of the familial cylindromatosis tumour-suppressor gene. *Nat Genet* 2000; **25:** 160–165.
2. Leonard N, Chaggar R, Jones C, *et al.* Loss of heterozygosity at cylindromatosis gene locus, *CYLD*, in sporadic skin adnexal tumours. *J Clin Pathol* 2001; **54:** 689–692.
3. Fehr A, Kovacs A, Löning T, *et al.* The MYB–NFIB gene fusion – a novel genetic link between adenoid cystic carcinoma and dermal cylindroma. *J Pathol* 2011; **224:** 322–327.
4. Ramsay RG, Gonda TJ. MYB function in normal and cancer cells. *Nat Rev Cancer* 2008; **8:** 523–534.
5. Bandopadhayay P, Ramkissoon LA, Jain P, *et al.* MYB–QKI rearrangements in angiocentric glioma drive tumorigenicity through a tripartite mechanism. *Nat Genet* 2016; **48:** 273–282.
6. Gualdrini F, Corvetta D, Cantilena S, *et al.* Addiction of MYCN amplified tumours to B-MYB underscores a reciprocal regulatory loop. *Oncotarget* 2010; **1:** 278–288.
7. Zhou Y, Ness SA. Myb proteins: angels and demons in normal and transformed cells. *Front Biosci* 2011; **16:** 1109–1131.
8. Calvisi DF, Simile MM, Ladu S, *et al.* Activation of v-Myb avian myeloblastosis viral oncogene homolog-like2 (*MYBL2*)–*LIN9* complex contributes to human hepatocarcinogenesis and identifies a subset of hepatocellular carcinoma with mutant *p53*. *Hepatology* 2011; **53:** 1226–1236.
9. Persson M, Andrén Y, Mark J, *et al.* Recurrent fusion of *MYB* and *NFIB* transcription factor genes in carcinomas of the breast and head and neck. *Proc Natl Acad Sci USA* 2009; **106:** 18740–18744.
10. Drier Y, Cotton MJ, Williamson KE, *et al.* An oncogenic *MYB* feedback loop drives alternate cell fates in adenoid cystic carcinoma. *Nat Genet* 2016; **48:** 265–272.
11. Rajan N, Andersson MK, Sinclair N, *et al.* Overexpression of *MYB* drives proliferation of *CYLD*-defective cylindroma cells. *J Pathol* 2016; **239:** 197–205.
12. Biggs PJ, Chapman P, Lakhani SR, *et al.* The cylindromatosis gene (*cyld1*) on chromosome 16q may be the only tumour suppressor gene involved in the development of cylindromas. *Oncogene* 1996; **12:** 1375–1377.
13. Brummelkamp TR, Nijman SM, Dirac AM, *et al.* Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-kB. *Nature* 2003; **424:** 797–801.
14. Suhasini M, Pilz RB. Transcriptional elongation of c-myb is regulated by NF-kB (p50/RelB). *Oncogene* 1999; **18:** 7360–7369.
15. Pannem RR, Dorn C, Hellerbrand C, *et al.* Cylindromatosis gene *CYLD* regulates hepatocyte growth factor expression in hepatic stellate cells through interaction with histone deacetylase 7. *Hepatology* 2014; **60:** 1066–1081.
16. Yang Y, Ran J, Liu M, *et al.* CYLD mediates ciliogenesis in multiple organs by deubiquitinating Cep70 and inactivating HDAC6. *Cell Res* 2014; **24:** 1342–1353.
17. Dai Y, Hung L, Chen R, *et al.* ON01910.Na inhibits growth of diffuse large B-cell lymphoma by cytoplasmic sequestration of sumoylated C-MYB/TRAF6 • complex. *Transl Res* 2016; •••: •••–•••. AQ3
18. Sun S. CYLD: a tumor suppressor deubiquitinase regulating NF-kB activation and diverse biological processes. *Cell Death Differ* 2010; **17:** 25–34.

**QUERIES TO BE ANSWERED BY AUTHOR**

**IMPORTANT NOTE: Please mark your corrections and answers to these queries directly onto the proof at the relevant place. DO NOT mark your corrections on this query sheet.**

**Queries from the Copyeditor:**

**AQ1.** Please confirm that given names (red) and surnames/family names (green) have been identified correctly

**AQ2.** Editor's note: DOI: 10.1002/path.4717. Please update this reference with volume and page numbers (and see also citation [11] in the reference list)

**AQ3.** insert volume and page numbers

# WILEY AUTHOR DISCOUNT CLUB

We would like to show our appreciation to you, a highly valued contributor to Wiley's publications, by offering a **unique 25% discount** off the published price of any of our books*.

All you need to do is apply for the **Wiley Author Discount Card** by completing the attached form and returning it to us at the following address:

The Database Group (Author Club)
John Wiley & Sons Ltd
The Atrium
Southern Gate
Chichester
PO19 8SQ
UK

Alternatively, you can **register online** at www.wileyeurope.com/go/authordiscount
Please pass on details of this offer to any co-authors or fellow contributors.

After registering you will receive your Wiley Author Discount Card with a special promotion code, which you will need to quote whenever you order books direct from us.

The quickest way to order your books from us is via our European website at:

## http://www.wileyeurope.com

Key benefits to using the site and ordering online include:
- Real-time SECURE on-line ordering
- Easy catalogue browsing
- Dedicated Author resource centre
- Opportunity to sign up for subject-orientated e-mail alerts

Alternatively, you can order direct through Customer Services at:
cs-books@wiley.co.uk, or call +44 (0)1243 843294, fax +44 (0)1243 843303

So take advantage of this great offer and return your completed form today.

Yours sincerely,

Verity Leaver
Group Marketing Manager
author@wiley.co.uk

*TERMS AND CONDITIONS

This offer is exclusive to Wiley Authors, Editors, Contributors and Editorial Board Members in acquiring books for their personal use. There must be no resale through any channel. The offer is subject to stock availability and cannot be applied retrospectively. This entitlement cannot be used in conjunction with any other special offer. Wiley reserves the right to amend the terms of the offer at any time.

# REGISTRATION FORM
# For Wiley Author Club Discount Card

To enjoy your 25% discount, tell us your areas of interest and you will receive relevant catalogues or leaflets from which to select your books. Please indicate your specific subject areas below.

**Accounting** [ ]
- Public [ ]
- Corporate [ ]

**Chemistry** [ ]
- Analytical [ ]
- Industrial/Safety [ ]
- Organic [ ]
- Inorganic [ ]
- Polymer [ ]
- Spectroscopy [ ]

**Encyclopedia/Reference** [ ]
- Business/Finance [ ]
- Life Sciences [ ]
- Medical Sciences [ ]
- Physical Sciences [ ]
- Technology [ ]

**Earth & Environmental Science** [ ]

**Hospitality** [ ]

**Genetics** [ ]
- Bioinformatics/ Computational Biology [ ]
- Proteomics [ ]
- Genomics [ ]
- Gene Mapping [ ]
- Clinical Genetics [ ]

**Medical Science** [ ]
- Cardiovascular [ ]
- Diabetes [ ]
- Endocrinology [ ]
- Imaging [ ]
- Obstetrics/Gynaecology [ ]
- Oncology [ ]
- Pharmacology [ ]
- Psychiatry [ ]

**Non-Profit** [ ]

**Architecture** [ ]

**Business/Management** [ ]

**Computer Science** [ ]
- Database/Data Warehouse [ ]
- Internet Business [ ]
- Networking [ ]
- Programming/Software Development [ ]
- Object Technology [ ]

**Engineering** [ ]
- Civil [ ]
- Communications Technology [ ]
- Electronic [ ]
- Environmental [ ]
- Industrial [ ]
- Mechanical [ ]

**Finance/Investing** [ ]
- Economics [ ]
- Institutional [ ]
- Personal Finance [ ]

**Life Science** [ ]

**Landscape Architecture** [ ]

**Mathematics** [ ]
**Statistics** [ ]

**Manufacturing** [ ]

**Materials Science** [ ]

**Psychology** [ ]
- Clinical [ ]
- Forensic [ ]
- Social & Personality [ ]
- Health & Sport [ ]
- Cognitive [ ]
- Organizational [ ]
- Developmental & Special Ed [ ]
- Child Welfare [ ]
- Self-Help [ ]

**Physics/Physical Science** [ ]

Please complete the next page /

I confirm that I am (*delete where not applicable):

a **Wiley** Book Author/Editor/Contributor* of the following book(s):
ISBN:
ISBN:

a **Wiley** Journal Editor/Contributor/Editorial Board Member* of the following journal(s):

SIGNATURE: …… Date: ……

---

**PLEASE COMPLETE THE FOLLOWING DETAILS IN BLOCK CAPITALS:**

TITLE: (e.g. Mr, Mrs, Dr) …… FULL NAME: ……

JOB TITLE (or Occupation): ……

DEPARTMENT: ……

COMPANY/INSTITUTION: ……

ADDRESS: ……

……

TOWN/CITY: ……

COUNTY/STATE: ……

COUNTRY: ……

POSTCODE/ZIP CODE: ……

DAYTIME TEL: ……

FAX: ……

E-MAIL: ……

---

**YOUR PERSONAL DATA**
We, John Wiley & Sons Ltd, will use the information you have provided to fulfil your request. In addition, we would like to:

1. Use your information to keep you informed by post of titles and offers of interest to you and available from us or other Wiley Group companies worldwide, and may supply your details to members of the Wiley Group for this purpose.
   [ ] Please tick the box if you do **NOT** wish to receive this information

2. Share your information with other carefully selected companies so that they may contact you by post with details of titles and offers that may be of interest to you.
   [ ] Please tick the box if you do **NOT** wish to receive this information.

**E-MAIL ALERTING SERVICE**
We also offer an alerting service to our author base via e-mail, with regular special offers and competitions. If you **DO** wish to receive these, please opt in by ticking the box [ ].

If, at any time, you wish to stop receiving information, please contact the Database Group (databasegroup@wiley.co.uk) at John Wiley & Sons Ltd, The Atrium, Southern Gate, Chichester, PO19 8SQ, UK.

---

**TERMS & CONDITIONS**
This offer is exclusive to Wiley Authors, Editors, Contributors and Editorial Board Members in acquiring books for their personal use. There should be no resale through any channel. The offer is subject to stock availability and may not be applied retrospectively. This entitlement cannot be used in conjunction with any other special offer. Wiley reserves the right to vary the terms of the offer at any time.

**PLEASE RETURN THIS FORM TO:**
Database Group (Author Club), John Wiley & Sons Ltd, The Atrium, Southern Gate, Chichester, PO19 8SQ, UK author@wiley.co.uk
Fax: +44 (0)1243 770154